目的：探讨紫杉醇、阿霉素每周方案与标准三周方案治疗局部晚期乳腺癌的近期疗效。方法选择2012年4月～2014年3月本院收治的局部晚期乳腺癌患者49例，随机分为两组，观察组24例患者给予紫杉醇70mg/m2，阿霉素30mg/m2，1次/周，连续3周，4周为1个周期；对照组25例患者给予紫杉醇135mg/m2，d1，阿霉素50mg/m2，d1，3周为1个周期；两组患者均治疗3个周期，比较两组近期疗效及毒副作用。结果观察组总有效率为87.50％；对照组总有效率为72.00％，两组总有效率比较，差异有统计学意义（P＜0.05）。术后病理结果显示新辅助化疗后观察组病理完全缓解率明显高于对照组，差异有统计学意义（P＜0.05）。两组恶心、呕吐、脱发、中性粒细胞减少、血小板减少、肌肉关节痛等毒副反应比较，差异均无统计学意义（P＞0.05）。结论紫杉醇、阿霉素每周方案新辅助化疗治疗局部晚期乳腺癌，剂量密度增加，总体疗效更高，且近期毒副反应无明显增加，值得进一步研究应用。%Objective To explore the recent curative effect of Paclitaxel, Pharmorubicin weekly neoadjuvant chemotherapy in the treatment of locally advanced breast cancer.Methods 49 patients with locally advanced breast cancer treated in our hospital from 2012 to 2014 were randomly divided into two groups. 24 patients of observation group were given paclitaxel 70mg/m2, pharmorubicin 30mg/m2, 1 time/week, continue 3 weeks, 4 weeks as a cycle; 25 patients of Control group were given Paclitaxel 135 mg/m2, Pharmorubicin 80mg/m2, d1, 3 weeks as a cycle; patients of two groups were treated for three cycles, recent curative effect and side effects of two groups were compared.Results Total effective rate was 87.50% in observation group, and 72.00% in control group, the difference between two groups was statistically significant (P<0.05). After neoadjuvant chemotherapy, Postoperative pathological results showed pathologic complete response rate of observation group was obviously higher than that of control group, the difference was statistically significant (P<0.05).The adverse reaction such as nausea, vomiting, hair loss, neutropenia, thrombocytopenia, and muscle joint pain compared, there were no statistically significant difference (P>0.05). Conclusion Paclitaxel, pharmorubicin weekly neoadjuvant chemotherapy in treatment of locally advanced breast cancer increases the dose density, with higher total efficacy and no obvious recent adverse reaction, worthy of further research and application.
展开▼
